Shopping Cart

Your shopping cart is currently empty

Ramatroban

Name: Ramatroban
Brand: TargetMol
SKU: T2396
Price: 32 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T2396Cas No. 116649-85-5

Alias BAY u3405

Ramatroban (BAY u3405) (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.

Ramatroban

Copy Product Info

😃Good

Purity: 98.75%

Catalog No. T2396Alias BAY u3405Cas No. 116649-85-5

Ramatroban (BAY u3405) (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.

Pack Size	Price	USA Warehouse	Global Warehouse
5 mg	$32	In Stock	In Stock
10 mg	$52	In Stock	In Stock
25 mg	$96	In Stock	In Stock
50 mg	$173	In Stock	In Stock
100 mg	$288	In Stock	In Stock
200 mg	$373	In Stock	In Stock
500 mg	$629	-	In Stock
1 mL x 10 mM (in DMSO)	$57	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:98.75%

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Ramatroban AI Summary

Ramatroban exhibits a diverse range of bioactivities, primarily characterized by its notable interactions with receptors and enzymes associated with platelet aggregation and prostaglandin pathways. It functions as an antagonist on human CRTH2 and Thromboxane A2 receptors, inhibiting PGD2-mediated receptor activation and various U-46,619 induced biological effects with IC50 and Ki values in the nanomolar range. The compound also demonstrates high-affinity binding to thromboxane receptors (Ki = 0.58 nM) and moderate affinity to CRTH2 receptors. It inhibits human Hematopoietic Prostaglandin D Synthase (H-PGDS) and multiple cytochrome P450 enzymes, suggesting potential modulatory effects in prostaglandin-mediated processes. Ramatroban's anti-platelet activity includes inhibition of collagen-induced platelet aggregation (IC50 = 50.0 nM) and U-46,619 induced human platelet aggregation (IC50 = 380.0 nM). Additionally, it shows inhibitory effects on eosinophil chemotaxis and degranulation, further implicating its role in inflammatory responses. The compound has demonstrated inhibition of SARS-CoV-2 3CL-Pro protease and displays antiviral activity against SARS-CoV-2 in various cellular assays. From a pharmacokinetic perspective, Ramatroban displays high plasma protein binding (PPB up to 97.5%) and moderate intrinsic clearance in human hepatocytes. Its logP value of 3.0 and varying logD values highlight its lipophilicity and distribution properties. In summary, Ramatroban is a potent bioactive molecule with significant inhibitory effects on platelet aggregation, prostaglandin-related receptors, and viral proteases, supporting its potential as a therapeutic agent across diverse biological pathways..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ramatroban (BAY u3405) (BAY u3405) is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis. It has been used in trials studying the treatment of Asthma.
Targets&IC50	DP2 (human):33.4 μM, CRTH2:113 nM, TXA2:14 nM
Synonyms	BAY u3405

Chemical Properties

Molecular Weight	416.47
Formula	C₂₁H₂₁FN₂O₄S
Cas No.	116649-85-5
Smiles	C(CC(O)=O)N1C2=C(C=3C1=CC=CC3)C[C@H](NS(=O)(=O)C4=CC=C(F)C=C4)CC2
Relative Density.	1.43 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 50 mg/mL (120.06 mM), Sonication is recommended.

Ethanol: 100 mM, Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.8 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.4011 mL	12.0057 mL	24.0113 mL	120.0567 mL
5 mM	0.4802 mL	2.4011 mL	4.8023 mL	24.0113 mL
10 mM	0.2401 mL	1.2006 mL	2.4011 mL	12.0057 mL
20 mM	0.1201 mL	0.6003 mL	1.2006 mL	6.0028 mL
50 mM	0.0480 mL	0.2401 mL	0.4802 mL	2.4011 mL
100 mM	0.0240 mL	0.1201 mL	0.2401 mL	1.2006 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc